Trials / Recruiting
RecruitingNCT06459310
Pilot Study on Evaluating the Geroprotective Effect of Metformin
A Phase II Exploratory Clinical Study Investigating the Geroprotective Effect of Metformin in Middle-aged and Elderly People
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 130 (estimated)
- Sponsor
- Xuanwu Hospital, Beijing · Academic / Other
- Sex
- Male
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The objective of this research is to assess the efficacy of oral metformin in mitigating the aging process in middle-aged and elderly males, to pinpoint sensitive indicators of human senescence, and to offer innovative frameworks and scientific insights for pharmaceutical interventions in aging.
Detailed description
Subjects in both the metformin hydrochloride extended-release tablets treatment group and the placebo group received two tablets (500 mg each) once daily after dinner, continuing for a one-year period of drug intervention.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Metformin Hydrochloride tablet | Extended release oral tablets, 1000 mg/day, single dose |
| DRUG | Placebo | Oral tablets, 1000 mg/day, single dose |
Timeline
- Start date
- 2024-06-30
- Primary completion
- 2026-09-30
- Completion
- 2028-07-31
- First posted
- 2024-06-14
- Last updated
- 2025-03-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06459310. Inclusion in this directory is not an endorsement.